The U.S. Food and Drug Administration greenlit AstraZeneca’s Farxiga (dapagliflozin) under priority review for the treatment of chronic kidney disease in patients at risk of progression with or without type 2 diabetes.

AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized Covid-19 patients at serious risk of developing complications.

AstraZeneca’s Farxiga improved survival chances for patients suffering from kidney disease, underscoring the medicine’s role outside the drug’s established field of diabetes.

AstraZeneca reported successful results from the company’s Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end-stage kidney disease.

The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for the treatment of heart failure in adults with reduced ejection fraction.

AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga (dapagliflozin) reduced the risk of the primary composite outcome of worsening heart failure or death from cardiovascular causes versus placebo, when added to standard of care.

Independent experts on an FDA advisory panel voted against the use of an already approved drug from Eli Lilly and Boehringer Ingelheim as an add-on to insulin therapy for type 1 diabetes.

AstraZeneca’s blockbuster drug Farxiga won U.S. approval as a treatment to reduce the chances of hospitalization for heart failure in adults with type 2 diabetes and other cardiovascular risks.

Invokana won U.S. approval to reduce the risk of end-stage kidney disease, cardiovascular death and worsening of kidney function in adults with type 2 diabetes and diabetic kidney disease.

AstraZeneca’s Farxiga was granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the diabetes drug and putting the medicine ahead of rivals.